Trial Outcomes & Findings for Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma (NCT NCT03278249)

Last Updated: 2024-09-19

Results Overview

Ketosis measured by serum beta-hydroxybuterate. Ketosis is defined as having serum beta-hydroxybuterate (BHB) at \> 0.05 mM. Participants' BHB levels were assessed at 6 weeks after starting the study. The number of participants who had BHB at \> 0.05 mM were considered to have entered into ketosis. 9 of 9 participants met this criteria.

Recruitment status

COMPLETED

Study phase

Target enrollment

12 participants

Primary outcome timeframe

6 weeks

Results posted on

2024-09-19

Participant Flow

Participant milestones

Participant milestones
Measure	Modified Atkins Ketogenic Diet Modified Atkins Ketogenic Diet in combination with Temodar and Radiation Modified Atkins Ketogenic Diet: Less than 20 grams of carbohydrates per day
Overall Study STARTED	12
Overall Study COMPLETED	9
Overall Study NOT COMPLETED	3

Reasons for withdrawal

Reasons for withdrawal
Measure	Modified Atkins Ketogenic Diet Modified Atkins Ketogenic Diet in combination with Temodar and Radiation Modified Atkins Ketogenic Diet: Less than 20 grams of carbohydrates per day
Overall Study Withdrawal by Subject	2
Overall Study Lost to Follow-up	1

Baseline Characteristics

Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Modified Atkins Ketogenic Diet n=9 Participants Modified Atkins Ketogenic Diet in combination with Temodar and Radiation Modified Atkins Ketogenic Diet: Less than 20 grams of carbohydrates per day
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	7 Participants n=5 Participants
Age, Categorical >=65 years	2 Participants n=5 Participants
Sex: Female, Male Female	6 Participants n=5 Participants
Sex: Female, Male Male	3 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	9 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants
Race (NIH/OMB) White	9 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants
Region of Enrollment United States	9 participants n=5 Participants

PRIMARY outcome

Timeframe: 6 weeks

Outcome measures

Outcome measures
Measure	Modified Atkins Ketogenic Diet n=9 Participants Modified Atkins Ketogenic Diet in combination with Temodar and Radiation Modified Atkins Ketogenic Diet: Less than 20 grams of carbohydrates per day
Number of Participants With Ketosis	9 Participants

SECONDARY outcome

Timeframe: 6 months

Progression Free Survival (PFS) is defined as the percentage of patients without progression at 6 months. Progression will be evaluated via Radiographic Assessment in Neuro-oncology (RANO) criteria: \>5 mm increase in maximal diameter, as well as ≥ 25% increase in the sum of the products of the progressing.

Outcome measures

Outcome measures
Measure	Modified Atkins Ketogenic Diet n=9 Participants Modified Atkins Ketogenic Diet in combination with Temodar and Radiation Modified Atkins Ketogenic Diet: Less than 20 grams of carbohydrates per day
Number of Participants With Progression Free Survival	6 Participants

SECONDARY outcome

Timeframe: 2 years

Outcome measures

Outcome measures
Measure	Modified Atkins Ketogenic Diet n=9 Participants Modified Atkins Ketogenic Diet in combination with Temodar and Radiation Modified Atkins Ketogenic Diet: Less than 20 grams of carbohydrates per day
Assessment of Survival	6 Participants

Adverse Events

Modified Atkins Ketogenic Diet

Serious events: 6 serious events

Other events: 9 other events

Deaths: 3 deaths

Serious adverse events

Serious adverse events
Measure	Modified Atkins Ketogenic Diet n=9 participants at risk Modified Atkins Ketogenic Diet in combination with Temodar and Radiation Modified Atkins Ketogenic Diet: Less than 20 grams of carbohydrates per day
Nervous system disorders Memory impairment	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Musculoskeletal and connective tissue disorders Muscle weakness, generalized or specific area (not due to neuropathy) - Extremity-lower	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Nervous system disorders Hydrocephalus	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Infections and infestations Infection with unknown ANC - Wound	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Blood and lymphatic system disorders Febrile neutropenia	22.2% 2/9 • Number of events 2 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Investigations Investigations, please specify	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Investigations Leukocytes (total WBC)	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Blood and lymphatic system disorders Lymphatics - Other (Specify, __)	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Investigations Neutrophils/granulocytes (ANC/AGC)	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Investigations Platelets	11.1% 1/9 • Number of events 2 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Vascular disorders Thrombosis/thrombus/embolism	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.

Other adverse events

Other adverse events
Measure	Modified Atkins Ketogenic Diet n=9 participants at risk Modified Atkins Ketogenic Diet in combination with Temodar and Radiation Modified Atkins Ketogenic Diet: Less than 20 grams of carbohydrates per day
Immune system disorders Allergic reaction	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Metabolism and nutrition disorders Anorexia	11.1% 1/9 • Number of events 2 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Psychiatric disorders Anxiety	22.2% 2/9 • Number of events 2 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Ear and labyrinth disorders Auditory/Ear - Other (Specify, __)	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Injury, poisoning and procedural complications Bruising	22.2% 2/9 • Number of events 2 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Nervous system disorders Cognitive disturbance	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Gastrointestinal disorders Constipation	66.7% 6/9 • Number of events 6 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Psychiatric disorders Depression	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Gastrointestinal disorders Diarrhea	33.3% 3/9 • Number of events 4 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Nervous system disorders Dizziness	33.3% 3/9 • Number of events 3 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
General disorders Edema: head and neck	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
General disorders Edema: limb	22.2% 2/9 • Number of events 2 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
General disorders Fatigue	77.8% 7/9 • Number of events 8 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Skin and subcutaneous tissue disorders Hair loss/alopecia (scalp or body)	22.2% 2/9 • Number of events 2 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Ear and labyrinth disorders Hearing	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Gastrointestinal disorders Heartburn/dyspepsia	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Blood and lymphatic system disorders Hemoglobin	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Investigations Hyperglycemia	11.1% 1/9 • Number of events 2 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Vascular disorders Hypertension	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Psychiatric disorders Insomnia	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Psychiatric disorders Irritability	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Investigations Leukocytes (total WBC)	22.2% 2/9 • Number of events 6 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Musculoskeletal and connective tissue disorders Muscle weakness, generalized or specific area (not due to neuropathy) - Extraocular	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Musculoskeletal and connective tissue disorders Muscle weakness, generalized or specific area (not due to neuropathy) - Extremity-upper	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Musculoskeletal and connective tissue disorders Muscle weakness, generalized or specific area (not due to neuropathy) - Facial	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Musculoskeletal and connective tissue disorders Muscle weakness, generalized or specific area (not due to neuropathy) - Ocular	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Musculoskeletal and connective tissue disorders Muscle weakness, generalized or specific area (not due to neuropathy) - Whole body/generalized	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Gastrointestinal disorders Nausea	33.3% 3/9 • Number of events 4 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Nervous system disorders Neurology - Other (Specify, __)	22.2% 2/9 • Number of events 3 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Nervous system disorders Neuropathy: sensory	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Investigations Neutrophils/granulocytes (ANC/AGC)	11.1% 1/9 • Number of events 3 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Eye disorders Ophthalmoplegia/diplopia (double vision)	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Infections and infestations Oral cavity-gums (gingivitis)	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Musculoskeletal and connective tissue disorders Pain - Back	22.2% 2/9 • Number of events 2 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Nervous system disorders Pain - Head/headache	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Musculoskeletal and connective tissue disorders Pain - Muscle	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Eye disorders Photosensitivity	11.1% 1/9 • Number of events 2 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Investigations Platelets	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Investigations Potassium, serum-low (hypokalemia)	22.2% 2/9 • Number of events 3 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Skin and subcutaneous tissue disorders Pruritus/itching	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Skin and subcutaneous tissue disorders Rash: acne/acneiform	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Skin and subcutaneous tissue disorders Rash: dermatitis associated with radiation - Chemoradiation	44.4% 4/9 • Number of events 4 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
General disorders Rigors/chills	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Nervous system disorders Seizure	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Infections and infestations Skin (cellulitis)	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Skin and subcutaneous tissue disorders Skin breakdown/decubitus ulcer	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Nervous system disorders Speech impairment (e.g., dysphasia or aphasia)	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Nervous system disorders Syncope (fainting)	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
General disorders Syndromes - Other (Specify, __)	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Vascular disorders Thrombosis/thrombus/embolism	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Nervous system disorders Tremor	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Renal and urinary disorders Urinary frequency/urgency	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Infections and infestations Urinary tract NOS	22.2% 2/9 • Number of events 2 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Eye disorders Vision-blurred vision	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Gastrointestinal disorders Vomiting	22.2% 2/9 • Number of events 2 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Investigations Weight loss	22.2% 2/9 • Number of events 3 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.
Injury, poisoning and procedural complications Wound	11.1% 1/9 • Number of events 1 • Adverse Events monitored/assessed for 2-3 months after pre-treatment visit 1, All-Cause Mortality monitored/assessed for up to 2 years The definitions do not differ from clinicaltrials.gov's definitions.

Additional Information

Rekha Chaudhary, MD, Adjunct-Associate Professor of Medicine

University of Cincinnati Cancer Center

Phone: 513-558-2119

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place